![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Consistency of Dolutegravir
Treatment Difference in HIV+ Treatment Naives at Week 96
|
|
|
Reported by Jules Levin
CROI 2015 Feb 23-26, Seattle, WA
Catherine Granier1, Naomi Givens1, Robert Cuffe2, Michael Aboud2, Louise Martin-Carpenter3, Kimberly Smith3, Clare Brennan4, Keith Pappa4, Brian Wynne4, Steve Almond5
1 R&D, GlaxoSmithKline, Uxbridge, Middlesex, United Kingdom;2 ViiV Healthcare, London, United Kingdom;3 ViiV Healthcare, Research Triangle Park, North Carolina, United States;4 GlaxoSmithKline, Research Triangle Park, North Carolina, United States;5 GlaxoSmithKline, Mississauga, Ontario, Canada
![CROI1.gif](../images/030415/030415-4/CROI1.gif)
![CROI2.gif](../images/030415/030415-4/CROI2.gif)
![CROI3.gif](../images/030415/030415-4/CROI3.gif)
![CROI4.gif](../images/030415/030415-4/CROI4.gif)
![CROI5.gif](../images/030415/030415-4/CROI5.gif)
![CROI6.gif](../images/030415/030415-4/CROI6.gif)
![CROI7.gif](../images/030415/030415-4/CROI7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|